www.dailypolitical.com ·
neurocrine biosciences q1 earnings call highlights
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedNeurocrine Biosciences reported strong Q1 2026 earnings driven by INGREZZA and CRENESSITY sales. The company reaffirmed guidance and expects to close the Soleno acquisition. Impact is company-specific, primarily affecting Neurocrine's revenue and margin. No broader sector or supply chain implications beyond the company's own pipeline and commercial execution.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue exceeded $800 million, up 44% YoY.
- INGREZZA sales reached $657 million in Q1 2026.
- CRENESSITY generated $153 million in sales with over 1,200 prescribers.
- Full-year INGREZZA guidance reaffirmed at $2.7-2.8 billion.
- Acquisition of Soleno Therapeutics anticipated to close.
Neurocrine's INGREZZA sales support a 2-4% stock increase within 48h; PHARMA_BIOTECH is affected up. Key risk: historical peer reactions suggest a more modest 1-2% move.
Sign in to see all sector verdicts, full thesis and counter-argument debate.